TNFRSF9 and neoplasm: Here, we show how a novel bispecific antibody (mAb2 TM) directed to CD137 and PD-L1 induces potent in vitro T cell activity in a PD-L1-dependent manner, and results in significant tumour control across three syngeneic tumour models without toxicity.